Activity, synthesis, storage, and messenger RNA of cyclooxygenase in intrauterine tissues of guinea pigs near term and during labor.
Whether the reported gestation-dependent increase in cyclooxygenase activity in gestational tissues is due to an accumulation of cyclooxygenase in vivo or an increasing capacity to synthesize cyclooxygenase in vitro is unknown. In this study in guinea pigs, COX activity was estimated from the net production rates of prostaglandins E(2) and F(2alpha) in the presence of optimal substrate concentrations. Cyclooxygenase activity in amnion increased between 45 days of gestation and labor in microsomes (150-fold in relation to PGF(2alpha) production and 116-fold in relation to PGE(2) production) and in tissue explants (42-fold in relation to PGF(2alpha) production). The capacity for de novo synthesis of cyclooxygenase after aspirin treatment increased nine-fold between 45 days of gestation and labor in amnion explants. Comparison of COX activity in amnion explants with or without prior aspirin treatment showed that COX activity is at least three-fold higher in controls than would be expected if the activity was due to de novo synthesis alone. Cyclooxygenase-2 mRNA predominated in amnion but neither cyclooxygenase-2 nor cyclooxygenase-1 mRNA levels (semi-quantitative RT-PCR) changed significantly. This suggests that the gestation-dependent increase in cyclooxygenase activity in guinea pig amnion is due in part to accumulation of cyclooxygenase in vivo, that COX-2 predominates, and that COX activity is not correlated with levels of COX mRNA.
Schellenberg
J-C
JC
Research Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, School of Biological Sciences, University of Auckland, New Zealand. jeanclaudeschellenberg@hotmail.com
Shelling
A N
AN
Van Ee
C C
CC
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D015237:Dinoprost / Q000096:biosynthesis; D015232:Dinoprostone / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D005260:Female; D006168:Guinea Pigs; D007527:Isoenzymes / Q000096:biosynthesis*; D007743:Labor, Obstetric; D008861:Microsomes / Q000378:metabolism; D011247:Pregnancy; D011270:Pregnancy, Animal; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis*; D020033:Protein Isoforms; D011720:Pyrazoles / Q000494:pharmacology; D012313:RNA / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013449:Sulfonamides / Q000494:pharmacology; D013997:Time Factors; D014018:Tissue Distribution; D014599:Uterus / Q000201:enzymology / Q000378:metabolism; D000096926:Benzenesulfonamides
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D015237:Dinoprost; D015232:Dinoprostone; D007527:Isoenzymes; D011451:Prostaglandin-Endoperoxide Synthases; D020033:Protein Isoforms; D011720:Pyrazoles; D012313:RNA; D012333:RNA, Messenger; D013449:Sulfonamides; C119130:4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; D000096926:Benzenesulfonamides